Dopamine agonists in the treatment of prolactinoma: are they still first choice?

$48.00 plus tax (Refund Policy)

Download / Buy Article:



Dopamine agonist therapy has been the cornerstone treatment for prolactinoma since the 1970s, replacing surgery in the primary management of this condition. These agents are effective in the management of prolactin excess, have a low side-effect profile, and in some cases may even be curative. However, recent studies of high dose dopamine agonists used in Parkinson's disease have raised the possibility that these drugs may be associated with cardiac valvulopathy. This paper discusses the modern use of dopamine agonists in a patient with prolactinoma.

Keywords: cardiac valvulopathy; dopamine agonist; prolactin; prolactinoma

Document Type: Research Article


Publication date: February 1, 2011

Related content



Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more